Even after the elimination of troglitazone from the market over ten years ago due to an increased risk of severe liver toxicity, the two remaining thiazolidinediones, rosiglitazone and pioglitazone, have been watched more closely than most new drugs on the market. It was quite clear these agents could result in weight gain, fluid retention, and even pulmonary edema.
